Eli Lilly is joining Amgen and Novartis in the pack of drugmakers aiming to treat cardiovascular disease by targeting lipoprotein(a). The Big Pharma landed a spot at the back of the bunch by handing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results